Drug discovery based on pharmacological interference with glycometabolism

Journal of China Pharmaceutical University

Volumn 37, Issue 1, 2006, Pages 1-8

  Sun, Hong Bin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Gluconeogenesis; Glycogen metabolism; Glycolysis; Interference in glycometabolism; Lactic acidosis

Indexed keywords

2 (BENZIMIDAZOL 2 YLTHIO) 1 (3,4 DIHYDROXYPHENYL) 1 ETHANONE; BAY 27 9955; CALCIUM; CP 368296; CS 917; FREE RADICAL; GLUCOSE; GLUCOSE DERIVATIVE; GLUFOSFAMIDE; GLYCOGEN; LACTIC ACID; LEVAMISOLE; LONIDAMINE; MB 05032; MB 06322; NEW DRUG; PSN 357; RO 28 0450; RO 28 2675; UNCLASSIFIED DRUG;

ASTROCYTE; BRAIN DISEASE; CARBOHYDRATE METABOLISM; DRUG DESIGN; DRUG STRUCTURE; ENERGY METABOLISM; GLYCOLYSIS; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; NERVE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TUMOR;

EID: 33644535113     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome[J]. Nature, 2001,414(6865):821-827.
2. Oikonomakos NG. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy[J]. Curr Protein Pept Sci, 2002,3(6):561-586.
3. Tracey WR, Treadway JL, Magee WP, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor[J]. Am J Physiol Heart Circ Physiol, 2004,286(3):H1 177-H1184.
4. Schnier JB, Nishi K, Monks A, et al. Inhibition of glycogen phosphorylase (GP) by CP-91, 149 induces growth inhibition correlating with brain GP expression[J]. Biochem Biophy Res Comm, 2003,309(1):126-134.
5. Nakahara M, Miyata K, Otani S, et al. A randomised, placebo controlled clinical trial of the aidose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients[J]. Br J Ophthalmol, 2005,89(3):266-268.
6. Staehr P, Hother-Nielsen O, Beck-Nielsen H. Hepatic glucose production: therapeutic target in type 2 diabetes? [J]. Diabetes Obes Metab, 2002,4(4):215-223.
7. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update[J]. Ann Internal Med, 2002,137(1):25-33.
8. Devries KM, Fox DE, Hammen PD, et al. Processes and intermediates for preparing 3 (S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2 (R)-hydroxy-4-phenyl-butyric acid: USA, US6410750[P].2005-06-25.
9. Bradley SE, Jeevaratnam RP, Krulle TM, et al. Pyrrolopyridine-2-carboxylic acid hydrazides: PCT, WO2005085245[P].2005-09-15.
10. (Sun HB). Chinese source. 2005:253-279.
11. Wen XA, Sun HB, Liu J, et al. Pentacyclic triterpenes. Part 1: The first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases[J]. Bioorg Med Chem Lett, 2005,15(22):4944-4948.
12. (Sun HB), (Wen XA), (Ni PZ). Chinese source. CN1634971[P].2005-07-06.
13. (Sun HB), (Wen XA), (Liu J), Chinese source. CN1682740[P].2005-10-19.
14. Wen XA, Zhang P, Liu J, et al. Pentacyclic Triterpenes. Part 2: Synthesis and biological activity of maslinic acid derivatives as inhibitors of glycogen phosphorylase [J]. Bioorg Med Chem Lett, 2006,16(3):722-726.
15. Connell RD. Glucagon antagonists for the treatment of type 2 diabetes [J]. Expert Opinion Therap Pat, 1999,9(6):701-709.
16. Madsen P, Knudsen LB, Wiberg FC, et al. Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists [J]. J Med Chem,1998,41:5150-5157.
17. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans[J]. Diabetologia, 2001,44(11):2018-2024.
18. Shen DM, Zhang FQ, Brady EJ, et al. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists [J]. Bioorg Med Chem Lett, 2005,15(20):4564-4569.
19. Barf T. Intervention of hepatic glucose production. Small molecule regulators of potential targets for type 2 diabetes therapy[J]. Mini Rev Med Chem, 2004,4(8):897-908.
20. Erion MD, van Poelje PD, Dang Q, et al. MB06322 (CS-917): A potent and selective inhibitor of fructose 1, 6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes[J]. Proc Natl Acad Sci USA, 2005,102(22):7970-7975.
21. Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes - A status review[J]. Curr Opin Drug Discov Develop, 2005,8(5):631-637.
22. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy[J]. Science, 2003,301 (5631):370-373.
23. Kamata K, Mitsuya M, Nishimura T, et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase[J]. Structure, 2004,12(3):429-438.
24. McKerrecher D, Allen JV, Bowker SS, et al. Discovery, synthesis and biological evaluation of novel glucokinase activators[J]. Bioorg Med Chem Lett, 2005,15(8):2103-2106.
25. Fyfe MCT, Gardner LS, Nawano M, et al. Tri (cyclo) substituted amide compounds: PCT, WO2004072031[P].2004-08-26.
26. Peetz D, Post F, Schinzel H, et al. Glycogen phosphorylase BB in acute coronary syndromes[J]. Clinical Chem Lab Med, 2005, 43 (12):1351-1358.
27. Kasischke KA, Vishwasrao HD, Fisher PJ, et al. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis [J]. Science, 2004,305(5680):99-103.
28. Tombaugh GC, Sapolsky RM. Evolving concepts about the role of acidosis in ischemic neuropathology[J]. J Neurochem, 1993,61:793-803.
29. Siesjo BK, Katsura K, Kristian T. Acidosis-related damage[J]. Adv Neurol, 1996,71:209-233.
30. Xiong ZG, Zhu XM, Chu XP, et al. Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels [J]. Cell, 2004,118(6):687-698.
31. Gao J, Duan B, Wang DG, et al. Coupling between NMDA receptor and acid-sensing ion channel contributes to ischemic neuronal death [J]. Neuron, 2005,48(4):635-646.
32. Chandy MJ, Ravindra J. Effect of dichloracetate on infarct size in a primate model of focal cerebral ischaemia [J]. Neurol India, 2000, 48:227-230.
33. Niwa M, Hara A, Iwai T, et al. Prevention of ischemia-induced hippocampal neuronal damage by 2-deoxy-D-glucose in gerbils[J]. Life Sci, 1999,64(18):PL193-PL198.
34. Oudard S, Poirson F, Miccoli L, et al. Mitochondria-bound hexokinase as target for therapy of malignant gliomas[J]. Intern J Cancer, 1995, 62(2):216-222.
35. Tidmarsh G. Treatment of benign prostatic hyperplasia: PCT, WO2004064735[P].2005-08-05.
36. Claustre S, Denier C, Lakhdar-Ghazal F, et al. Exploring the active site of trypanosoma brucei phosphofructokinase by inhibition studies: specific irreversible inhibition[J]. Biochem, 2002,41(32):10183-10193.
37. Guminska M, Kedryna T, Marchut E. The effect of levamisole on energy-metabolism in ehrlich ascites tumor-cells in vitro [J]. Biochem Pharmacol, 1986,35(24):4369-4374.
38. Tidmarsh G. Treatment of cancer with 2-deoxyglucose: US, US2005245462[P].2005-11-03.
39. Lampidis T, Priebe W. Manipulation of oxidative phosphorylation for hypersensitizing tumor cells to glycolytic inhibitors: PCT, WO0182926 [P].2001-11-08.
40. +-D-glucose cotransporter SAAT1 [J]. Proc Natl Acad Sci USA, 1998, 95(6): 2914-2919.
41. Briasoulis E, Pavlidis N, Terret C, et al. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group[J]. Eur J Cancer, 2003,39(16):2334-2340.